Head And Neck Cancer NM Flashcards
Lip and oral cavity cancer most common type
Tobacco and alco - - SCC 95%
Lip and oral cavity cancer
Most common location
Tongue (oral tongue more likely LN)
FOM (more likely LN)
Gingiva
Lip and oral cavity cancer
Premalignant
Leukoplakia
Erythroplakia
Lip and oral cavity cancer T1
Lip and oral cavity cancer T2
Lip and oral cavity cancer T3
Lip and oral cavity cancer T4a
Lip and oral cavity cancer T4b
Lip and oral cavity cancer N
Lip and oral cavity cancer M
Lung
Bone
Liver
Ca of lip LN
IA
IB
CA of alveolar ridge or hard palate LN
Low potential for MTS
IB
II-IV
retropharyngeal - less common
Level VII = ant sup mediastinal still regional
Lip and oral cavity cancer CT limit
Small lesions
Mucosal surface
Dental amalgam streak artifact
Lip and oral cavity cancer PET/CT
Unknown primary
False positive: muscle, brown fat, lymphoid tissue, mucosa
Oropharynx p16- risk
Tobacco
Alco
Men
Elderly
Oropharynx p16- subsites
Base of tongue (lingual tonsil)
Palatine tonsils
Pharyngeal walls
Soft palate and uvula
Hypopharynx T3
Hemilarynx fixation
Oropharynx cancer M
Lung
Bone
Liver
Oropharynx p16- most important prognostic factor
Regional LN
Palatine tonsils and base of tongue - - II, III, retropharyngeal
Posterior pharyngeal wall - - retropharyngeal
Base of tongue - - bilateral
Also I, IV and V
Oropharynx p16 important
Keratizing
Mucosal ulceration
Resistant
Poor response
Worse prognosis
Higher rate of M
Locoregional recurrence
Oropharynx p16- T1
Oropharynx p16- T2
Oropharynx p16- T3
Oropharynx p16- T4a
Oropharynx p16- T4b
Oropharynx p16+ most common location
Base of tongue (lingual tonsil)
Palatine tonsil
Oropharynx p16+ risk
Younger men
No tobacco or alco
High status
Increased number of partners
HPV type 16
Also types 18, 31, 33
Oropharynx p16+ N
Oropharynx p16+ regional LN
More significant than p16-
II and III
Oropharynx p16+ important
Non keratizing
Cystic nodes - - negative on PET
Better prognosis, respond
More M1, atypical sites
Adult with new cystic lymphadenopathy in upper neck
Oropharynx p16+
Oropharynx p16+ T1
Oropharynx p16+ T2
Oropharynx p16+ T4a
Oropharynx p16+ T4b
Oropharynx p16+ T3
Hypopharynx
95% SCC
Hypopharynx subsites
Sinus pyriformis - - encase ICA - - >270°
Hypopharyngeal wall (lateral and posterior)
Postcricoid region - - Plammer-Vinson sy, Paterson-Kelly sy
Hypopharynx M
Lung
Bone
Liver
Hypopharynx regional LN
Early dissemination
75% at presentation
20-40% contralateral Nodal MTS at diagnosis
II-IV
Retropharyngeal
VI
Medistianal nodes (VII) are still regional
40% of clinically N0 - - pathologically N+
Hypopharynx PET
Staging
Prior to endoscopy
Hypopharynx important
60% keratizing
“hot potato” voice
Poor survival
Worst prognosis of all head and neck SCC
Hypopharynx risk
Men
Tobacco
Alco
Fe def
Vit C def
Hypopharynx T1
Hypopharynx T2
Hypopharynx T3
Hypopharynx T4a
Hypopharynx T4b
Hypopharynx T4b
Hypopharynx T4b
Oropharynx p16+
Nasopharynx keratizing SCC
Smoke, HPV
Locally advanced at presentation
Nasopharynx non keratizing SCC
Differentiated type
Undifferentiated type - most common 90%
EBV
Better prognosis
Nasopharynx basaloid SCC
Men, 30-40, 50-60
China endemic
Nasopharynx T
Nasopharynx N
Nasopharynx M
Bone
Lung
Liver
Rare
High potential
Poor prognosis
Highest rate of LN MTS among all SCC of head and neck
Nasopharynx
Nasopharynx regional LN
80-90% at presentation
Retropharyngeal 70%
II 70%
Spinal accessory chain V
Well controlled by radiation unlike other SCC
Nasopharynx CT
Mass in lateral pharyngeal recess of nasopharynx with deep extension and cervical adenopathy
Most frequent - lateral wall = fossa of Rosenmueller
Nasopharynx PET
Strong avidity
Submucosal tumor
Perineural spread - - mandibular nerve
Superior in restating and evaluating treatment effectiveness
Nasopharynx T0
Malignant cervical lymphadenopathy +EBV
Nasopharynx presentation
Unilateral hearing loss
Painless upper cervical lymphadenopathy
Nasopharynx stage I-II treatment
Radio
Cures 60-90%
Nasopharynx most powerful prognostic factor
Stage at presentation
Nasopharynx T1